Decreasing levels of tumour necrosis factor alpha and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors.

Samuelsson, L; Gottsäter, Anders; Lindgärde, Folke

Published in:
Diabetes, Obesity and Metabolism

DOI:
10.1046/j.1463-1326.2003.00264.x

Published: 2003-01-01

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Decreasing levels of tumour necrosis factor α and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors

L. Samuelsson, A. Gottsäter and F. Lindgärde
Department of Vascular Diseases, University Hospital, S-205 02 Malmö, Sweden

Aim: Obesity is associated with increased levels of inflammatory mediators. The objective of this study was to evaluate changes in the leucocyte derived inflammatory mediators tumour necrosis factor alpha (TNF-α), interleukin 6 (IL-6) and the isoprostane 8-epi-prostaglandin (PG) F2α during BMI lowering with orlistat (Xenical®, Roche) or placebo.

Methods: TNF-α, IL-6, and 8-epi PGF2α evaluated in 376 subjects aged 18–75 years with BMI 28–38 kg/m² before and after 1 year of double-blind, randomized treatment with orlistat 120 mg or placebo three times daily.

Results: Weight reduction was associated with decreasing (p < 0.001) levels of TNF-α and IL-6 in both orlistat and placebo groups. After 12 months, TNF-α was lower (p < 0.05) in the orlistat compared with the placebo group. In the orlistat group, the change in TNF-α correlated with change in s-glucose (r = 0.22; p = 0.01), and the change in 8-epi-PGF2α correlated with changes in s-cholesterol (r = 0.27; p < 0.001) and s-LDL-cholesterol (r = 0.28; p < 0.001).

Conclusion: Weight reduction was associated with decreasing levels of both TNF-α and IL-6. After 12 months of treatment, TNF-α levels were lower in orlistat than in placebo-treated subjects. Whether these results translate into reduced incidence of cardiovascular disease remains to be elucidated.

Keywords: inflammation, TNF-α, IL-6, isoprostane, 8-epi-PGF2α

Received 2 December 2002; returned for revision 7 January 2003; revised version accepted 10 February 2003

Introduction

Excess adiposity increases the risk of atherosclerotic cardiovascular disease, independently of other risk factors, such as diabetes mellitus, arterial hypertension and dyslipidemia [1-4]. In atherosclerosis, there is a low level, chronic inflammatory process, with enhanced plasma levels of inflammatory mediators [5], e.g. C-reactive protein (CRP) [6], a hepatic acute-phase protein. In apparently healthy individuals, increased levels of CRP predict atherosclerotic manifestations during long time follow up [7]. C-reactive protein is largely regulated by circulating levels of interleukin 6 (IL-6) [7,8]. Both IL-6 and tumour necrosis factor alpha (TNF-α) are expressed [9,10], and released [9,11] from adipose tissue. Strong relations have been found between body mass index (BMI), per cent body fat and levels of IL-6 [5,9,12], TNF-α [5], and CRP [5]. Weight reduction has recently been demonstrated to reduce IL-6 and TNF-α levels and subsequently improve endothelial function in a small female population without cardiovascular risk factors [13], supporting the concept that obesity is linked to a low-level chronic inflammatory state that might be related to cardiovascular disease.
Isoprostanes are prostaglandin F₂-like compounds, derived from arachidonic acid through lipid peroxidation on cell membranes and LDL-particles, catalysed by oxygen free particles in a non-cyclooxygenase pathway [14,15]. Isoprostanes are measured as markers for lipid peroxidation. Isoprostane levels are increased in high age [16], hypercholesterolemia [16] diabetes mellitus [14,17] and smoking [18]. 8-epi-prostaglandin (PG) F₂α is an isoprostane with biological effects such as platelet activation and smooth muscle cell proliferation [18], believed to contribute to atherosclerosis and thrombosis [18]. Furthermore, 8-epi-prostaglandin (PG) F₂α levels are of special interest in this context as they are increased in several rat models of obesity [19–21].

Several pharmacological compounds for treatment of obesity are available [22]. One such drug is orlistat, which by inhibition of gastrointestinal lipases lowers absorption of dietary fat [22]. Orlistat has been shown to reduce weight in obese subjects at increased risk for cardiovascular disease [23]. In this study, we tested the hypothesis that BMI lowering during orlistat and diet treatment in obese subjects was associated with decreasing levels of the leucocyte derived inflammatory mediators TNF-α and IL-6, or of 8-epi-PGF₂α.

Methods

Subjects

This work is part of a larger study of 376 men and non-pregnant women aged 18–75 years (mean 53.5 years) with BMI 28–38 kg/m² (table 1 [23]). All patients had at least one of the following obesity-associated risk factors for cardiovascular disease: fasting serum (s-) glucose ≥ 6.7 mmol/l, or type 2 diabetes treated with sulphonylurea or metformin but not tiazolidines or insulin; total s-cholesterol ≥ 6.5 mmol/l and/or low density lipoprotein (LDL) cholesterol ≥ 4.2 mmol/l on at least two occasions, or lipid-lowering medication; diastolic blood pressure ≥ 90 mm Hg on at least two occasions, or antihypertensive medication. Numbers of patients receiving medication for cardiovascular risk factors were similar in both groups (table 1).

Exclusion criteria were prior myocardial infarction within 3 months, surgery for weight reduction, active gastrointestinal disorders, pancreatic disease, post-surgical adhesions, excessive alcohol intake or substance abuse, systemic steroid treatment other than hormone replacement, and use of certain drugs altering body weight or plasma lipids, such as appetite suppressants, resins, retinoids and fish oil supplements. The study protocol conformed to the Declaration of Helsinki. The ethics committees of all study centres and the Swedish Medical Product Agency approved the study. All participants gave written informed consent.

Methods

This was a 54-week, double-blind, randomized, placebo-controlled study conducted at 33 Swedish primary care centres. After screening, eligible patients entered a 2-week lead-in period during which they received single-blind placebo and were encouraged to follow a mildly hypocaloric diet based on national dietary recommendations, designed to provide ~30% of energy intake as fat. Energy content was calculated from estimated basal metabolic rate multiplied by 1.3 to estimate total daily energy expenditure. From this, 600 kcal day⁻¹ was subtracted to give a mildly hypocaloric diet. The minimum calorie intake was 1200 kcal day⁻¹.

Table 1 Demographic and metabolic characteristics of treatment groups at screening [mean ± SD (range) or n(%)]. BP = blood pressure

<table>
<thead>
<tr>
<th></th>
<th>Orlistat (n = 190)</th>
<th>Placebo (n = 186)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male/female</td>
<td>66/124</td>
<td>71/115</td>
</tr>
<tr>
<td>Age (years)</td>
<td>53.7 ± 9.4 (27–74)</td>
<td>53.2 ± 9.9 (28–75)</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>96.1 ± 13.7 (65–134)</td>
<td>95.9 ± 13.5 (65–130)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>33.2 ± 3.0 (27.5–38.7)</td>
<td>33.2 ± 3.1 (27.2–40.4)</td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>6.15 ± 1.21 (3.7–10.2)</td>
<td>6.06 ± 1.19 (3.7–9.9)</td>
</tr>
<tr>
<td>LDL cholesterol (mmol/l)</td>
<td>3.75 ± 1.38 (0.0–7.5)</td>
<td>3.66 ± 1.41 (0.0–7.7)</td>
</tr>
<tr>
<td>Fasting glucose (mmol/l)</td>
<td>6.62 ± 2.53 (4.0–17.5)</td>
<td>6.35 ± 1.96 (3.9–18.1)</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>5.7 ± 1.2 (4.3–12.2)</td>
<td>5.5 ± 0.9 (4.3–10.5)</td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>146 ± 19 (99–217)</td>
<td>145 ± 17 (108–190)</td>
</tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>87 ± 10 (60–110)</td>
<td>88 ± 10 (60–118)</td>
</tr>
<tr>
<td>Antihypertensive drugs</td>
<td>84 (44)</td>
<td>74 (40)</td>
</tr>
<tr>
<td>Lipid-lowering drugs</td>
<td>36 (18)</td>
<td>27 (15)</td>
</tr>
<tr>
<td>Antidiabetic drugs</td>
<td>40 (21)</td>
<td>39 (21)</td>
</tr>
</tbody>
</table>
After the 2-week lead-in period, patients were randomized to receive orlistat (Xenical®, Roche) 120 mg or placebo three times daily together with the mildly hypocaloric diet. After 6 months, the energy content was reduced by a further 300 kcal day to account for expected reduction in energy requirements as a result of weight loss. Patients visited the clinic regularly for dietary counselling. If treatment compliance fell below 60%, the subject was withdrawn from the study. Changes in medication for cardiovascular risk factors were assessed.

Plasma (p-) samples for analysis of TNF-α, IL-6 and 8-epi PGF2α were taken before and after 12 months of treatment.

**P-TNF-α and p-IL-6 Analyses**

p-TNF-α and p-IL-6 were measured by ELISA using commercially available test kits (Pharmingen, San Diego, CA, USA) according to procedures described by the manufacturer.

**8-epi-PGF2α Analysis**

p-8-epi-PGF2α was measured by enzyme immunoassay using commercially available test kits (Cayman Chemical Company, Ann Arbor, MI, USA) according to procedures described by the manufacturer.

**Statistics**

Differences between orlistat and placebo groups were analysed by the Wilcoxon rank sum test. For comparisons within groups, absolute changes in the study variables were analysed using the signed Wilcoxon rank sum test. p-values < 0.05 were considered significant. For comparisons between groups, relative changes were analysed, calculated as the individual difference for each subject between baseline and 12 months, divided by the baseline value and multiplied by 1000. Correlations were analysed using Spearman’s correlation co-efficient. Because of the multiple correlations tested, only p-values = 0.01 were considered significant for correlations. All analyses were performed using SAS software, version 8.2e.

**Results**

**All 376 subjects**

Weight reduction occurred in both orlistat and placebo groups (5.9 ± 5.5% (5.6 ± 5.2 kg) vs. 4.6 ± 5.4% (4.3 ± 5.9 kg) of initial body weight; p < 0.05). This, as well as results concerning waist/hip ratio, blood pressure, s-lipid profile, fasting s-glucose, HbA1c and reduction of antidiabetic medication has been presented elsewhere [23]. Body mass index did not correlate with TNF-α, IL-6 or 8-epi-PGF2α at baseline. Weight reduction was associated with decreasing (p < 0.001) levels of TNF-α and IL-6 in both orlistat and placebo groups (table 2 and figure 1). After 12 months, TNF-α was lower (p < 0.05) in the orlistat compared to the placebo group (table 2). In the orlistat group, the change in TNF-α correlated with the change in s-glucose (r = 0.22; p = 0.01), and the change in 8-epi-PGF2α correlated with changes in s-cholesterol (r = 0.27; p < 0.001) and s-LDL-cholesterol (r = 0.28; p < 0.001). No such correlations were seen in the placebo group. There were no correlations in any of the groups between the amount of weight reduction and changes in TNF-α, IL-6 or 8-epi-PGF2α (data not shown).

**Subjects With a Weight Reduction ≥ 10%**

Sixty-three subjects had lost ≥ 10% of their weight after 12 months. Tumour necrosis factor α was then lower (p < 0.01) in the orlistat compared to the placebo group (table 2). Tumour necrosis factor decreased (p < 0.001) in both groups, but the relative decrease in TNF was larger (p < 0.01) in the orlistat than in the placebo group. IL-6 decreased significantly (p < 0.01) in the placebo group, whereas no changes occurred in the orlistat group.

**Diabetic Subjects**

Among the 98 diabetic subjects, TNF decreased significantly (p < 0.001) in both groups, whereas IL-6 decreased significantly (p < 0.01) only in the orlistat group.

**Subjects with Arterial Hypertension**

Among the 280 subjects with arterial hypertension, both TNF-α and IL-6 decreased significantly (p < 0.001) in both groups.

**Discussion**

In this study of obese subjects with risk factors for cardiovascular disease, we demonstrate that the reduction of BMI achieved with both orlistat and placebo was accompanied by decreasing levels of the leucocyte-derived inflammatory mediators TNF-α and IL-6, which...
are known to be elevated in cardiovascular disease [5].
On the other hand, the BMI reduction was not associated
with any decrease in levels of the oxidative stress marker
isoprostane 8-epi-PGF$_{2\alpha}$ [18].
Decreasing levels of TNF-$\alpha$ and IL-6 have previously
been reported during weight reduction with non-
pharmacological methods in a smaller exclusively female
population without cardiovascular risk factors [13], and
IL-6 levels also decrease during short time follow-up of
weight reduction in adolescents [24] and obese women
[25]. Furthermore, TNF-$\alpha$ expression in adipose tissue
has been shown to decrease during weight reduction
[26]. As orlistat treatment is associated with signifi-
cantly larger weight reductions than placebo [23,27],
even larger effects upon TNF-$\alpha$ and IL-6 might have
been expected during orlistat treatment than during
weight reduction with non-pharmacological methods
only. It is therefore interesting to note that TNF-$\alpha$ was
lower in the whole orlistat treated group after 12 months,
and that among subjects losing more than 10% of their
initial weight, the relative decrease in TNF-$\alpha$ was larger
(p < 0.01) in the orlistat than in the placebo group. Apart
from this, only small differences concerning TNF-$\alpha$, IL-6
and 8-epi-PGF$_{2\alpha}$ were seen between orlistat and placebo
groups in our study, however. Whether these differences
in cytokine levels between study groups were due to
specific effects of orlistat upon cytokines, or to the
differences in weight reduction between the two study
groups [23] cannot be safely concluded. The fact that
we, like previous investigators [28], found no significant
correlations between the degree of weight reduction and
the degree of decrease in TNF-$\alpha$ primarily supports the
hypothesis of cytokine-specific effects of orlistat as
explanation for the differences between TNF-$\alpha$ in the
orlistat compared with the placebo group after
12 months. However, there are no data available from
cell culture or animal models to support such a hypo-
thesis. Although it is unclear whether the greater reduc-
tion in TNF-$\alpha$ is clinically relevant, our results indicate
that adverse effects of orlistat upon inflammatory mark-
ers are highly unlikely.

In mainly non-diabetic obese women [25], but not in
this study, plasma concentrations of IL-6 correlated with
BMI and percent body fat. Furthermore, decreases in IL-6
have been reported to correlate with decreases in BMI
during short time weight reduction in children and ado-
lescents [24]. Although we demonstrate decreasing IL-6
during weight reduction, we did not find any correla-
tions between the degrees of decrease in BMI and IL-6
during our longer follow-up of a larger patient material
at higher age, and with cardiovascular risk factors. Pre-
vious diet therapy for obesity as well as the presence of,
and treatment for, the different cardiovascular risk factors
in our subjects might perhaps have influenced cytokine
levels and interfered with their relationships with BMI.

Among diabetic subjects, TNF-$\alpha$ decreased in both
orlistat and placebo groups. Circulating TNF-$\alpha$ has
been proposed to mediate insulin resistance in the
obese [10,29], and decreasing TNF-$\alpha$ levels might there-
fore contribute to improving insulin sensitivity after

---

**Table 2 Absolute values (pg/ml, median and range). O, orlistat, P, placebo**

<table>
<thead>
<tr>
<th></th>
<th>Whole material</th>
<th>≥10% Weight reduction</th>
<th>Diabetes mellitus</th>
<th>Hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n = 190)</td>
<td>(n = 186)</td>
<td>(n = 36)</td>
<td>(n = 54)</td>
</tr>
<tr>
<td>0 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNF-$\alpha$</td>
<td>13.6</td>
<td>14.1</td>
<td>17.9</td>
<td>13.8</td>
</tr>
<tr>
<td>(0.1–89.8)</td>
<td>(0.3–96.1)</td>
<td>(3.0–46.5)</td>
<td>(0.4–41.6)</td>
<td>(1.1–46.7)</td>
</tr>
<tr>
<td>IL-6</td>
<td>5</td>
<td>4.8</td>
<td>5.4</td>
<td>5.4</td>
</tr>
<tr>
<td>(0.007–460)</td>
<td>(0.007–221)</td>
<td>(0.001–40.8)</td>
<td>(0.4–46.6)</td>
<td>(2.0–52.3)</td>
</tr>
<tr>
<td>8-epiPGF$_{2\alpha}$</td>
<td>215</td>
<td>210</td>
<td>227</td>
<td>187</td>
</tr>
<tr>
<td>12 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNF-$\alpha$</td>
<td>3.8*, §</td>
<td>5.9*</td>
<td>3.11§</td>
<td>6.7§</td>
</tr>
<tr>
<td>(0.001–130)</td>
<td>(0.001–144)</td>
<td>(0.001–14.4)</td>
<td>(1.0–35.9)</td>
<td>(0.001–69.2)</td>
</tr>
<tr>
<td>IL-6</td>
<td>3.21</td>
<td>3.55</td>
<td>4.1</td>
<td>3.8§</td>
</tr>
<tr>
<td>(0.001–335)</td>
<td>(0.001–142)</td>
<td>(0.2–246)</td>
<td>(0.1–19.8)</td>
<td>(0.001–15.1)</td>
</tr>
<tr>
<td>8-epiPGF$_{2\alpha}$</td>
<td>218</td>
<td>228</td>
<td>249</td>
<td>225</td>
</tr>
<tr>
<td>(30–3446)</td>
<td>(30–1297)</td>
<td>(39–5104)</td>
<td>(50–3446)</td>
<td>(73–3269)</td>
</tr>
</tbody>
</table>

*p < 0.05 compared with placebo group.
†p < 0.01 compared with placebo group.
‡p < 0.01 compared with same group at diagnosis.
§p < 0.001 compared with same group at diagnosis.
weight loss [10,28]. Such mechanisms might also explain the relations between decreases in TNF-α and s-glucose in orlistat treated subjects in our study. Relationships between these results and the decreasing proportion of patients using antidiabetic medication during the study [23] cannot be excluded.

We failed to show decreases in 8-epi-PGF$_{2α}$ levels during weight reduction in our study. Isoprostane-lowering effects such as those observed in obese rats after antioxidant vitamin E supplementation [20] does apparently not occur during weight reduction in obese humans with cardiovascular risk factors [14,16,17], or the concomitant pharmacological treatment [14] which might influence isoprostane levels. The correlations between changes in 8-epi-PGF$_{2α}$ and changes in S-LDL- and total cholesterol in our study are interesting, however, as 8-epi-PGF$_{2α}$ levels are increased in hypercholesterolemia [16]. A change in one of these two variables seems to be related to a change in the same direction in the other variable. Our results do not justify speculations upon whether decreasing 8-epi-PGF$_{2α}$ levels might contribute to beneficial effects of cholesterol lowering upon cardiovascular disease [30], however. Such a hypothesis needs to be tested by 8-epi-PGF$_{2α}$ analysis in subjects treated with potent cholesterol-lowering agents.

Fig. 1. Decreasing (p < 0.001) TNF-α and IL-6 but unchanged 8-epi-PGF$_{2α}$ in orlistat and placebo groups at 0 and 12 months. After 12 months, TNF-α is lower (p < 0.05) in the orlistat than in the placebo group. Values are median, ●, orlistat, ■, placebo.
In summary, weight reduction was associated with decreasing levels of both TNF-α and IL-6 in obese subjects with risk factors for cardiovascular disease. Furthermore, after 12 months of treatment, TNF-α levels were lower in orlistat than in placebo treated subjects. As CRP, endothelial reactivity or in vivo blood flow were not assessed in our study, it remains to be elucidated whether our results translate into reduced incidence of cardiovascular disease, as suggested by beneficial effects of reduction of cytokine levels upon vascular responses to L-arginine in healthy subjects [13].

Acknowledgements

The authors thank Barbro Palmqvist, MLT, for skilful technical assistance, and Fredrik Hansson, HH-statistik, Lund, Sweden, for expert statistical calculations and advice. This study was supported by the Ernhold Lundström Foundation, the Hulda Ahlmroth Foundation, Lund University Research Funds, Research Funds of Malmö University Hospital, the Foundation for Research upon Diabetes and Vascular Disease, and Roche AB, Stockholm, Sweden.

References

22. Lindgårde F, on behalf of the orlistat Swedish multimorbidity study group. The effect of orlistat on body weight...


